ClinicalTrials.gg
Active, not recruitingNCT05653349VAYHIT1Updated Nov 12, 2026

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

A Phase 3 interventional study of Ianalumab and Placebo in Primary Immune Thrombocytopenia (ITP), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 99 sites in 25 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Study completion moved2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Enrollment
2nd of 12
226 · median 39
Started
2023
with 2 others
Phase 3
4 of 17
none open now
Registered
8th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 3, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in increasing the rate of stable response off treatment at 12 months (SROT-12) in adult participants with primary ITP.

Read the detailed description

This is a multi-center, randomized, double-blind Phase 3 study to assess the efficacy and safety of two different doses of ianalumab compared to placebo in adults with primary ITP (platelets count \<30 G/L) who require first-line standard-of-care corticosteroids.

After completion of the screening period, the participants will enter the randomized treatment period (ianalumab/placebo with standard of care corticosteroids).

After the treatment period, all participants will enter the follow-up period to be monitored for efficacy and safety or safety only depending on how they respond to the study treatment.

The efficacy and safety follow-up period will last until treatment failure or up to 39 months after randomization of the last patient, whichever occurs first. Safety follow-up period will be performed for at least 20 weeks and up to 2 years after the last ianalumab/placebo dose.

The primary endpoint was updated in May 2026 to stable response off treatment at 12 months (SROT-12). The previous primary endpoint, time to treatment failure (TTF), remains in the study as a key secondary objective.

03

Conditions studied

  • Primary Immune Thrombocytopenia (ITP)

Keywords

  • Primary immune thrombocytopenia (ITP)
  • ianalumab
  • VAY736
  • B-cell depletion
  • B-cell Activating Factor Receptor (BAFF-R) blockade
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Signed prior to participation in the study.
  • Male or female participants aged 18 years and older on the day of signing informed consent
  • Primary ITP diagnosed within 3 months before initiating ITP therapy (, IVIG)
  • count below 30 G/L before starting any first-line ITP therapy (corticosteroids, IVIG)
  • Response (platelet count >=50 G/L) to corticosteroids (+/- IVIG) at any time prior to randomization. Note: Platelet count measured within 7 days of platelet transfusion will not be considered as response.

Key Exclusion Criteria:

  • Evans syndrome or any other cytopenia (patients with low grade anemia related to bleeding or iron deficiency are eligible)
  • Current life-threatening bleeding
  • Previous ITP treatment, including splenectomy, except for corticosteroids and/or IVIG initiated as first-line therapy for up to 28 days before randomization and rescue corticosteroids and/or IVIG given prior to confirmed diagnosis of primary ITP .
  • Prior use of B-cell depleting therapy (e.g., rituximab).
  • below 1.0 G/L at randomization
  • Participants with concurrent coagulation disorders and/or receiving anti-platelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid

Other protocol-defined Inclusion/Exclusion may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    Ianalumab Lower dose

    Lower dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)

    Biological: Ianalumab · Drug: Corticosteroids

  • Experimental
    Ianalumab Higher dose

    Higher dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)

    Biological: Ianalumab · Drug: Corticosteroids

  • Placebo comparator
    Placebo

    Placebo administered intravenously with corticosteroids oral or parental (if clinically justified)

    Drug: Placebo · Drug: Corticosteroids

Interventions

  • BiologicalIanalumab

    Intravenous infusion, prepared from concentrate solution

    Also known as: VAY736

  • DrugPlacebo

    Intravenous infusion, prepared from matching placebo

  • DrugCorticosteroids

    Oral or parental (if clinically justified)

06

What researchers measure

Primary outcomes

  1. Rate of Stable Response off treatment at 12 months (SROT-12)

    A participant will be considered in SROT-12 if at least 75% of the platelet counts collected between visits Week 53 Day 1 and Week 65 Day 1 (Study Days 352 and 463) qualify as Response. Response is any platelet counts of at least 50 G/L in the absence of rescue treatment or new immune thrombocytopenia (ITP) treatment).

    Time frame: 12 months after last patient completed treatment

Secondary outcomes

  1. Time from randomization to Treatment Failure (TTF) (Key Secondary Endpoint)

    Time to Treatment Failure (TTF) is defined as the time from randomization until the first of the following events/situation indicative of treatment failure: platelet count below 30 G/L later than 8 weeks from randomization, need for a rescue treatment later than 8 weeks from randomization, intake of rescue treatment (e.g., corticosteroids, Intravenous immunoglobulins (IVIG), or platelet transfusion) given later than 8 weeks from randomization, start of new Immune Thrombocytopenia (ITP) treatment whenever it occurs, death (whatever the cause).

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient

  2. Complete Response (CR) rate in each treatment group

    Complete Response (CR) rate at each timepoint defined as the proportion of participants with any platelet count of at least 100 G/L in the absence of rescue treatment or new ITP treatment.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  3. Response (R) rate in each treatment group

    Response (R) rate at each timepoint defined as the proportion of participants with any platelet count of at least 50 G/L in the absence of rescue treatment or new ITP treatment.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  4. Time to complete response in each treatment group

    Time from randomization to date of first complete response.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  5. Duration of response in each treatment group

    Time from achievement of complete response to loss of complete response

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  6. Stable response at 6 months

    Percentage of participants with at least 2 platelet count collected at month 6 (between study dates 107 and 183) and at least 66% of platelet counts qualified as a response

    Time frame: At 6 months

  7. Stable response at 1 year

    Percentage of participants with at least 2 platelet counts collected at year 1 (between study days 296 and 379) and at least 66% of platelet counts qualified as a response

    Time frame: At 1 year

  8. Percentage of participants with bleeding events overall and by World Health Organization (WHO) bleeding scale severity

    This is to assess the incidence and severity of bleeding in each treatment arm

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  9. Number of participants with bleeding events overall and by World Health Organization (WHO) bleeding scale severity

    This is to assess the number and severity of bleeding in each treatment arm

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  10. Number of participants receiving rescue treatment (cummulative dose/duration of steroids exposure)

    This is to assess the number of participants receiving rescue treatment.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  11. Percentage of participants receiving rescue treatment (cummulative dose/duration of steroids exposure)

    This is to assess the need of rescue treatment in each treatment group by percentage.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  12. Cumulative dose/duration of steroids exposure

    Duration of exposure to corticosteroids calculated from randomization (first dose) to end of study or last last contact date (if the participant is lost to follow-up).

    Time frame: From screening to end of study (up to 39 months after randomization of last patient)

  13. Change from baseline on T scores of the PROMIS SF v1.0 Fatigue 13a

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 13a includes 13 items that assess fatigue

    Time frame: From screening (baseline) till end of study (up to 39 months after randomization of last patient)

  14. Change from baseline in ITP-PAQ domain scores

    The ITP-PAQ is a 44 item scale for measuring HRQoL in adults with ITP across ten scales: Symptoms, Bother-Physical Health, Fatigue/Sleep, Activity, Fear, Psychological Health, Work, Social Activity, Women's Reproductive Health, and Overall QoL. Each item is rated on a Likert type scale

    Time frame: From screening (baseline) till end of study (up to 39 months after randomization of last patient)

  15. Change from baseline in frequency of CD19+ B cell counts

    Post baseline frequency (%within the CD45) of CD19+ B cell counts compare to baseline.

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  16. Change from baseline in absolute number of CD19+ B cell counts

    Post baseline absolute number of CD19+ B cell counts compare with baseline

    Time frame: Randomization to end of study (up to 39 months after randomization of last patient)

  17. Time to first occurrence of B-cell recovery

    B-cell recovery is defined as ≥80% of baseline and ≥LLOQ, or ≥50 cells/μL

    Time frame: Randomization to end of study (up to 39 months after randomized of last patient)

  18. Change from baseline in inmmunoglobulins

    Change from baseline in immunoglobulin levels

    Time frame: Randomization to end of study (up to 39 months after last randomized patients)

  19. PK parameters: AUClast

    AUClast: area under the curve from time zero till the last measurable concentration sampling time (tlast)

    Time frame: After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)

  20. PK parameter: AUCtau

    Area under the curve calculated to the end of a dosing interval (tau)

    Time frame: After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)

  21. PK parameters: Cmax

    Maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration

    Time frame: After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)

  22. PK parameters: Tmax

    Time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration

    Time frame: After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)

  23. PK parameters: Accumulation ratio Racc

    Accumulation ratio calculated using AUC values obtained between the last and first dose

    Time frame: After last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)

  24. Incidence of anti-ianalumab antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assess the immunogenicity of ianalumab

    Time frame: Up to Week 33

  25. Titer of anti-ianalumab antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assess the immunogenicity of ianalumab

    Time frame: Up to Week 33

07

Study locations

99 sites
  • Yuma Regional Medical Center
    Yuma, Arizona 85364, United States
  • Community Cancer Institute
    Clovis, California 93611, United States
  • Compassionate Care Res Group Inc
    Fountain Valley, California 92708, United States
  • University of Colorado Anschutz
    Aurora, Colorado 80045, United States
  • DH Cancer Research Center LLC
    Margate, Florida 33063, United States
  • Uni of Chi Medi Ctr Hema and Onco
    Chicago, Illinois 60637, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Med Center
    Boston, Massachusetts 02215, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Hematology Oncology Association of Rockland
    Nyack, New York 10960, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Mays Cancer Ctr Uthsa Mdacc
    San Antonio, Texas 78229, United States
  • Community Cancer Trials of Utah
    Ogden, Utah 84405, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1280AEB, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1414DRK, Argentina
  • Novartis Investigative Site
    San Miguel Tucuman, Tucumán Province T4000DPK, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1039AAC, Argentina
  • Novartis Investigative Site
    Córdoba, 5000, Argentina
  • Novartis Investigative Site
    Garran, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Wooloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Roeselare, West Vlaanderen 8800, Belgium
  • Novartis Investigative Site
    Brasschaat, 2930, Belgium
  • Novartis Investigative Site
    Bruges, 8000, Belgium
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Beijing, Beijing Municipality 100044, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518037, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050000, China
  • Novartis Investigative Site
    Luoyang, Henan 471003, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
  • Novartis Investigative Site
    Changzhou, Jiangsu 213004, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Kunming, Yunnan 650101, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310006, China
  • Novartis Investigative Site
    Bengbu, 233004, China
  • Novartis Investigative Site
    Dalian, 116000, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Ostrava, Poruba 708 52, Czechia
  • Novartis Investigative Site
    Prague, 100 34, Czechia
  • Novartis Investigative Site
    Prague, 128 08, Czechia
  • Novartis Investigative Site
    Caen, 14033, France
  • Novartis Investigative Site
    Chambéry, 73000, France
  • Novartis Investigative Site
    Le Mans, 72000, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    New Territories, Hong Kong 999077, Hong Kong
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380013, India
  • Novartis Investigative Site
    Rishikesh, Uttarakhand 249203, India
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Trieste, TS 34129, Italy
  • Novartis Investigative Site
    Vicenza, VI 36100, Italy
  • Novartis Investigative Site
    Nagakute, Aichi-ken 4801195, Japan
  • Novartis Investigative Site
    Shibukawa, Gunma 3770280, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608604, Japan
  • Novartis Investigative Site
    Okayama, Okayama-ken 7011192, Japan
  • Novartis Investigative Site
    Iruma-gun, Saitama 3500495, Japan
  • Novartis Investigative Site
    Chiba, 2600852, Japan
  • Novartis Investigative Site
    Fukuoka, 8158555, Japan
  • Novartis Investigative Site
    Gifu, 5008513, Japan
  • Novartis Investigative Site
    Osaka, 5438555, Japan
  • Novartis Investigative Site
    Kuching, Sarawak 93586, Malaysia
  • Novartis Investigative Site
    George Town, 10050, Malaysia
  • Novartis Investigative Site
    Johor Bahru, 80100, Malaysia
  • Novartis Investigative Site
    Kuala Selangor, 68000, Malaysia
  • Novartis Investigative Site
    Mexico City, Mexico City 06720, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Grålum, 1714, Norway
  • Novartis Investigative Site
    Bucharest, 030171, Romania
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Murcia, 30008, Spain
  • Novartis Investigative Site
    Seville, 41013, Spain
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Samsun, Atakum 55200, Turkey (Türkiye)
  • Novartis Investigative Site
    Aydin, Efeler 09100, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Birmingham, West Midlands B15 2TH, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG5 1PB, United Kingdom
  • Novartis Investigative Site
    Hanoi, 100000, Vietnam
  • Novartis Investigative Site
    Ho Chi Minh City, 70000, Vietnam
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Oct 2026, 44 months.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2029 → Aug 2028, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 16, 2022
StartActual
Feb 3, 2023
Primary completionActual
Oct 29, 2026
CompletionEst.
Aug 11, 2028was Jan 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 14 sites removed
Show 2 added (1 Argentina, 1 Belgium)
  • Novartis Investigative Site · Buenos Aires, Argentina
  • Novartis Investigative Site · Roeselare, Belgium
Show 14 removed
  • Oncology Care Associates · Bethesda, United States
  • Michigan Center of Medical Research · Farmington Hills, United States
  • Metro Minnesota CCOP · Saint Louis Park, United States
  • St Vincent Frontier Cancer Center · Billings, United States
  • Optum Health · Lake Success, United States
  • STAT Research Inc · Dayton, United States
  • Novartis Investigative Site · Caba, Argentina
  • Novartis Investigative Site · Melbourne, Australia
  • Novartis Investigative Site · Roeselare, Belgium
  • Novartis Investigative Site · Leuven, Belgium
  • Novartis Investigative Site · Essen, Germany
  • Novartis Investigative Site · Giessen, Germany
  • Novartis Investigative Site · Madrid, Spain
  • Novartis Investigative Site · Salamanca, Spain
Nov 9, 2026
Study completion
Jan 5, 2029→Aug 11, 2028
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Study completion Jan 5, 2029→Aug 11, 2028
  2. Nov 9, 2026
    2 sites added, 14 sites removed
    Show 2 added (1 Argentina, 1 Belgium)
    • Novartis Investigative Site · Buenos Aires, Argentina
    • Novartis Investigative Site · Roeselare, Belgium
    Show 14 removed
    • Oncology Care Associates · Bethesda, United States
    • Michigan Center of Medical Research · Farmington Hills, United States
    • Metro Minnesota CCOP · Saint Louis Park, United States
    • St Vincent Frontier Cancer Center · Billings, United States
    • Optum Health · Lake Success, United States
    • STAT Research Inc · Dayton, United States
    • Novartis Investigative Site · Caba, Argentina
    • Novartis Investigative Site · Melbourne, Australia
    • Novartis Investigative Site · Roeselare, Belgium
    • Novartis Investigative Site · Leuven, Belgium
    • Novartis Investigative Site · Essen, Germany
    • Novartis Investigative Site · Giessen, Germany
    • Novartis Investigative Site · Madrid, Spain
    • Novartis Investigative Site · Salamanca, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05653349
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Feb 3, 2023
Primary completion
Oct 29, 2026
Completion
Aug 11, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion